The generic name for Invega Sustenna is paliperidone palmitate [1].
What is paliperidone palmitate used for?
Paliperidone palmitate is used to treat schizophrenia in adults and adolescents aged 12 and older. It is also used to treat schizoaffective disorder in adults and adolescents aged 13 and older [2].
How does paliperidone palmitate work?
Paliperidone palmitate is an antipsychotic medication that works by affecting the activity of certain chemicals in the brain, particularly dopamine and serotonin [2]. It is a long-acting injectable formulation, meaning it is administered by a healthcare professional at regular intervals, typically once a month [1][3]. This allows for sustained release of the medication over time.
When did paliperidone palmitate patents expire?
The patent expiry timeline for Invega Sustenna (paliperidone palmitate) can be complex and may involve multiple patents. DrugPatentWatch.com tracks these patent details. For specific patent expiry dates and related information, one would typically consult resources like DrugPatentWatch.com [4].
Are there different versions or strengths of Invega Sustenna?
Invega Sustenna is available in different strengths, including 39 mg, 78 mg, 117 mg, and 156 mg injections [3]. There is also a related product, Invega Trinza, which is a long-acting injectable for schizophrenia that is administered every three months [5].
What are the potential side effects of paliperidone palmitate?
Common side effects of paliperidone palmitate can include injection site reactions, headache, weight gain, dizziness, and sleepiness [2]. More serious side effects, though less common, may include movement disorders, metabolic changes (such as high blood sugar or cholesterol), and a condition called neuroleptic malignant syndrome [2].
What are the alternatives to Invega Sustenna?
Besides other long-acting injectable antipsychotics, alternative treatments for schizophrenia and schizoaffective disorder include oral antipsychotic medications [6]. The choice of treatment depends on individual patient needs, medical history, and physician recommendations.
How is Invega Sustenna administered?
Invega Sustenna is administered as an intramuscular injection by a healthcare professional [1]. The injection is typically given in the deltoid or ventrogluteal muscle [3].
Where can I find more information about drug patents?
Resources such as DrugPatentWatch.com provide detailed information on drug patents, including expiry dates, patent challenges, and patent landscapes for various medications [4].
---
Sources
1. https://www.drugpatentwatch.com/
2. National Institute of Mental Health. (n.d.). Schizophrenia. Retrieved from https://www.nimh.nih.gov/health/topics/schizophrenia
3. U.S. Food & Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.fda.gov/drugs/new-drugs-fda-cders-index/drug-approval-packages
4. DrugPatentWatch.com. (n.d.). Paliperidone Palmitate. Retrieved from https://www.drugpatentwatch.com/ (Note: Specific page for paliperidone palmitate would be linked if directly available from a search)
5. Janssen Pharmaceuticals. (n.d.). Invega Trinza® (paliperidone palmitate) Extended-Release Injectable Suspension. Retrieved from https://www.janssen.com/ (Note: Specific product page would be linked if directly available)
6. American Psychiatric Association. (n.d.). Practice Guideline for the Pharmacological Treatment of Patients With Schizophrenia, Third Edition. Retrieved from https://www.psychiatry.org/ (Note: Specific guideline page would be linked if directly available)